IVTM market to reach $2.5b by 2033 as sepsis and stroke fuel surge in medical disposables

Its adoption grows in cardiac, neurocritical, post-arrest care.

The global intravascular temperature management (IVTM) market is projected to have a compound annual growth rate of 8.9% from 2026 to 2033, reaching a value of $2.5b by the end of the forecast period, according to Verified Market Reports.

The Asia-Pacific region is the fastest-growing region, driven by rapid urbanisation and healthcare modernisation initiatives across China, India, Southeast Asia, and parts of Oceania.

North America and Europe dominate the market due to advanced critical care infrastructure and centralised healthcare systems, whilst adoption of IVTM in the Middle East is supported by state-backed investment in world-class healthcare facilities.

Latin America and parts of Africa remain nascent but strategically relevant over the long term.

Clinical standardisation of targeted temperature management is one of the key drivers of market growth, as IVTM systems are increasingly embedded into post–cardiac arrest, neurocritical care, and complex cardiac surgery protocols.

The market is also shifting from single-use hypothermia indications to broader applications, such as aggressive fever management in sepsis, stroke, and traumatic brain injury, which increase addressable patient volumes and support recurring revenue models tied to disposables.

Manufacturers are introducing smart solutions with predictive algorithms, real-time feedback, and integration with ICU monitoring platforms, reducing clinician workload, improving protocol adherence, and creating defensible differentiation.

Clearer clinical guidelines and bundled payment models in North America and parts of Europe are lowering adoption barriers, with vendors that align product claims with evidence-based outcomes better positioned to accelerate market penetration strategies.

Despite growth, adoption barriers remain, as IVTM systems cost more than single-use catheters and are considered invasive due to potential infection risks.

Variability in clinical guidelines across different regions can slow the adoption of IVTM for newer applications, such as sepsis-related fever control.

Market leaders are now moving beyond devices to integrated therapy ecosystems, bundling catheters, consoles, service contracts, and data analytics to achieve long-term customer value by 2033.